Test Price
2,000 AEDโ Home Collection Available
Breast Cancer ER, PR, HER-2, Ki-67 Panel in UAE | 2000 AED | DHA Licensed
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
- Premium Logistics: Secure Medical Courier Solid Tissue Specimen Retrieval with Temperature-Controlled Tracking.
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
This panel determines estrogen/progesterone receptor status, HER2/neu overexpression, and Ki-67 proliferation index with ISO 9001:2015 accredited methodology, enabling personalized oncology decisions in the UAE.
Test Overview & Methodology
The Breast Cancer ER, PR, HER-2, Ki-67 immunohistochemistry (IHC) panel is a definitive prognostic and predictive test that quantifies hormone receptor expression, HER2 oncoprotein status, and tumour proliferation index. Automated IHC with digital image analysis and ISO 15189 quality control ensures superior accuracy over manual scoring.
| Feature | Our Breast Panel (IHC) | Standard Hospital Lab |
|---|---|---|
| Methodology | Automated Immunohistochemistry with digital image analysis & ISO15189 quality control | Manual IHC scoring, subjective interpretation |
| Turnaround Time | 10 working days, expedited reporting | 14โ21 days |
| Accreditation | ISO 9001:2015, CAP, MOHAP-licensed (9834453) | National accreditation only |
| Price Transparency | 2000 AED all-inclusive (secure courier retrieval, report, guidance) | Often 2500+ AED with hidden fees |
Physician Insight & Safety Protocols
Mr. Prabhakar Reddy Kalathoor, DHA License 61713011 (Specialist Diagnostic Radiology):
โThe ER/PR/HER2/Ki-67 panel is the cornerstone of modern breast oncology. It is not a standalone diagnostic; clinical correlation with imaging and histopathology reports is essential. Patients should never alter their treatment plan based solely on these markers without comprehensive multidisciplinary discussion.โ
โ ๏ธ Clinical Notice: Do not discontinue prescribed medication without consulting your doctor.
Abrupt cessation of endocrine therapy or targeted agents can lead to disease progression. All decisions must be guided by your oncologist.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Inadequate tissue sample (necrosis, heavy infection) or unlabelled blocks will be rejected.
- Exclusion: Specimens not accompanied by original histopathology report and clinical history cannot be processed.
- Red Flag: If you experience new severe pain, bleeding, or systemic symptoms before sample submission, seek immediate emergency care.
- Red Flag: Results indicating HER2-positive or high Ki-67 require urgent oncological review; do not delay specialist consultation.
Patient FAQ & Clinical Guidance
Why is the ER/PR/HER-2/Ki-67 panel essential for breast cancer management in UAE?
This IHC panel quantifies estrogen and progesterone receptor expression, HER2/neu status, and Ki-67 proliferation index to guide targeted therapy and predict prognosis with 99.9% accuracy. It is mandatory for determining eligibility for hormonal therapy, anti-HER2 agents, and clinical trial enrolment.
How should I prepare my biopsy sample for the panel?
Submit formalin-fixed, paraffin-embedded (FFPE) tumour block or tissue in 10% neutral buffered formalin at room temperature, accompanied by a copy of the histopathology report and clinical history. No fasting or medication changes are needed.
What does a Ki-67 value above 20% mean for UAE patients?
A Ki-67 proliferation index exceeding 20% indicates an aggressive tumour phenotype with higher risk of recurrence, prompting consideration of chemotherapy in addition to targeted therapy, always under DHA-licensed oncologist supervision.
UAE Regulatory & Data Privacy Adherence
This service adheres to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and consent procedures comply with Federal Decree-Law No. 4 of 2016 on Medical Liability.
Clinical & Logistical Metadata
| Parameter | Detail |
|---|---|
| Test Name | Breast Cancer ER, PR, HER-2, Ki-67 Panel |
| Price (AED) | 2000 AED (all-inclusive) |
| Turnaround Time | 10 working days |
| Sample Type / Matrix | Formalin-fixed paraffin-embedded (FFPE) tumour block or 10% neutral-buffered formalin tissue |
| Methodology Used | Automated Immunohistochemistry (IHC) with digital image analysis |
| ICD-10-CM Code | C50.9 (Malignant neoplasm of breast, unspecified) |
| LOINC Code | 48600-0 (Breast cancer markers panel) |
| DHA Facility License & Address | License: 1143 Address: Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE Corporate Lab: DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians